Leads from the MMWR. Need for malaria prophylaxis by travelers to areas with chloroquine-resistant Plasmodium falciparum.
D000349:Africa; D000962:Antimalarials / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D002738:Chloroquine / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000187:drug effects; D011247:Pregnancy; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*; D014195:Travel; D014481:United States
D000962:Antimalarials; D004338:Drug Combinations; D013424:Sulfanilamides; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine